What is the pathway of vitamin D metabolism, including its synthesis, hepatic and renal activation, degradation, and recommended supplementation strategies for deficiency?

Vitamin D Metabolism

Vitamin D undergoes a well-defined metabolic pathway beginning with cutaneous synthesis or dietary intake, followed by sequential hepatic 25-hydroxylation to form 25(OH)D (the storage form and best biomarker of status), then renal 1-alpha-hydroxylation to produce 1,25-dihydroxyvitamin D (the active hormone), with degradation primarily via 24-hydroxylase. 1

Synthesis and Sources

Vitamin D is technically not a true vitamin since it can be endogenously synthesized in adequate amounts with sufficient sun exposure 1. The pathway begins with:

• Cutaneous synthesis: 7-dehydrocholesterol in skin converts to cholecalciferol (vitamin D3) upon UV-B radiation exposure 2
• Dietary sources: Vitamin D3 from oil-rich fish (salmon, mackerel, herring) and vitamin D2 (ergocalciferol) from UV-irradiated yeast and mushrooms 3
• Supplementation: Both D2 and D3 forms are used in fortified foods and supplements, though D3 is preferred 1

Important caveat: Seasonal UV-B variation, clothing, limited outdoor time, and skin pigmentation have made the general population increasingly reliant on oral intake rather than endogenous synthesis 1, 2.

Hepatic Activation (First Hydroxylation)

Whether synthesized in skin or ingested, vitamin D undergoes 25-hydroxylation in the liver to form 25-hydroxyvitamin D [25(OH)D] 1. This process is:

• Not tightly regulated, making 25(OH)D concentration the most accurate reflection of vitamin D status 1
• The major circulating metabolite with relatively long half-life 4
• Measured clinically to assess vitamin D status (both D2 and D3 forms) 5

Renal Activation (Second Hydroxylation)

The second hydroxylation step involves 1-alpha-hydroxylation, primarily occurring in the kidneys, to produce 1,25-dihydroxyvitamin D [1,25(OH)2D or calcitriol], the hormonally active metabolite 1. Key regulatory features:

• Stimulated by: Parathyroid hormone (PTH) 2
• Suppressed by: Calcium and fibroblast growth factor-23 (FGF-23) 1, 2
• Extrarenal synthesis: Many tissues can perform local 1-alpha-hydroxylation under cytokine influence for paracrine regulation 2

Degradation Pathway

Vitamin D metabolites are inactivated primarily through:

• 24-hydroxylase (CYP24A1): The main degradation enzyme acting on both 25(OH)D and 1,25(OH)2D 1
  • Produces 24R,25(OH)2D3 as initial product from 25(OH)D3 4
  • Induced by FGF-23 in chronic kidney disease 1
• 3-epimerase: Converts 25(OH)D3 to 3-epi-25(OH)D3 4
• Biliary excretion: Metabolites are secreted with bile acids and reabsorbed in terminal ileum 1

Mechanism of Action

The active metabolite 1,25(OH)2D exerts effects through:

• Genomic pathway: Binds to vitamin D receptor (VDR) expressed in most tissues, regulating gene transcription for proteins like calcium-binding protein and osteocalcin 2, 6
• Non-genomic pathway: Rapid effects via plasma membrane receptor and second messengers (cyclic AMP) affecting pancreas, vascular smooth muscle, and immune cells 2
• Primary physiologic role: Promoting intestinal calcium absorption critical for skeletal and mineral homeostasis 1

Conditions Affecting Metabolism

Several pathologic states substantially alter vitamin D physiology 1:

• Malabsorption: Terminal ileal disease, short gut syndrome, Roux-en-Y gastric bypass
• Nephrotic syndrome: Loss of vitamin D metabolites bound to vitamin D-binding protein and albumin in urine
• Chronic kidney disease: Increased 24-hydroxylase activity via FGF-23 induction
• Medications: Various pharmacologic agents affect hydroxylase activity 1

Supplementation Strategies for Deficiency

Based on the 2024 Endocrine Society guidelines 1:

Defining Deficiency

• Deficiency: 25(OH)D <20 ng/mL (<50 nmol/L)
• Suboptimal: 20-30 ng/mL (50-75 nmol/L) 7
• Optimal: 30-50 ng/mL (75-125 nmol/L) for disease prevention 7
• Target for clinical outcomes: >50 ng/mL (125 nmol/L) 8

Supplementation Approach

• First-line: Cholecalciferol (vitamin D3) preferred over ergocalciferol (D2) 7
• General population: 2000 IU/day (50 mcg/day) to achieve levels >30 ng/mL 9
• Enhanced protection: 4000-6000 IU/day to achieve 40-70 ng/mL for greater disease prevention 9
• Daily dosing preferred over intermittent high-dose regimens 1

Factors Affecting Response

Baseline 25(OH)D, body mass index, ethnicity, vitamin D type (D2 vs D3), and genetics significantly affect response to supplementation 5. Obesity, dark skin pigmentation, and advanced age are major risk factors requiring higher doses 3, 2.

Critical point: The skeletal effects of vitamin D depend on adequate calcium intake, so supplementation should ensure sufficient calcium availability 1, 2.